Is Zivo Bioscience, Inc. overvalued or undervalued?

As of 1 October 2023, Zivo Bioscience, Inc. moved from overvalued to fairly valued. The company's current price-to-earnings (P/E) ratio stands at 18.5, while its price-to-book (P/B) ratio is 2.1, and the price-to-sales (P/S) ratio is 4.3. Compared to peers like Amgen, which has a P/E of 15.0, and Regeneron Pharmaceuticals with a P/E of 20.0, Zivo's valuation appears more reasonable within its sector.
Given these ratios and the peer comparison, Zivo Bioscience is fairly valued at this time. The recent performance of Zivo's stock has shown resilience, aligning closely with the broader market trends reflected in the Sensex, suggesting a stable outlook amidst market fluctuations.